|
Thomas A. Krenitsky, Ph.D. - Principal founder, President, and CEO. Dr. Krenitsky is a recognized authority on drug discovery and development. After receiving his Ph.D. in Biochemistry from Cornell University, he did a postdoctoral fellowship at Sloan-Kettering Institute for Cancer Research and then joined the research faculty at Yale Medical School. In 1966, he joined the research group of Drs. George H. Hitchings and Gertrude B. Elion at Burroughs Wellcome Co (BW Co.). Drs. Hitchings and Elion received the 1988 Nobel Prize in Medicine for the outstanding series of innovative drugs that emanated from their laboratories. Dr. Krenitsky worked directly with these outstanding scientists until their retirements. In 1983, he succeeded Dr. Elion as head of the Experimental Therapy Division and in 1989 was appointed Vice President of Research at BW Co. In this capacity, he had responsibility for over 500 professional scientists and support staff. Under his leadership, much of the development pipeline at BW Co.was discovered. In addition to drug discovery, a large part of the preclinical development functions were performed in the Research Unit at BW Co. under Dr. Krenitsky’s direction. He also played a key role in licensing activities, including assessment of drug candidates and negotiations on terms. He was a member of the BW Co. committee overseeing the clinical development of drug candidates from 1983 to 1995. Dr. Krenitsky is the author or co-author of 90 full scientific papers and 32 abstracts dealing with drug discovery. He is inventor on 30 issued US patents with more pending. He served on the Board of Directors of The Burroughs Wellcome Fund from 1990 to 1996. Dr. Krenitsky is an inventor of the drug nelarabine that is being clinically studied for T-cell malignancies and was intimately involved in the discovery and development of VALTREX®. | 